Review of Immunotherapy Progress in Lung Cancer: Bispecific Antibodies and CAR-T Platforms

A 23.2 KB document authored by Lei He, last updated on April 21, 2026, reviews recent progress in immunologically oriented therapeutic strategies for lung cancer. The text focuses on bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and emerging in vivo CAR-engineering modalities, discussing clinical rationale, evidence, and challenges.

Use Cases

• Literature review on bispecific antibodies and CAR-T therapy for lung cancer based on the described clinical and translational evidence.
• Analysis of challenges in lung cancer immunotherapy based on described topics like on-target off-tumor toxicity and cytokine release syndrome.
• Comparative study of therapeutic strategies based on the review of bispecific antibodies versus emerging in vivo CAR-engineering platforms.

Strengths

• Document is under the CC-BY-4.0 license, allowing for broad sharing and adaptation.
• Specific focus on lung cancer immunotherapy modalities like bispecific antibodies and CAR-T therapy is clearly stated.

Limitations

• The dataset is a 23.2 KB DOCX file, indicating a very limited textual scope rather than a large-scale data collection.
• Row count and column-level documentation are absent; the content's structure and data semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare, author Lei He

Collection Method

Likely a literature review or summary document.

Freshness

Last updated 2026-04-21 05:30:43; freshness should be verified.